Selinexor

XPOVIO®

Verified

Overview

Selinexor (Xpovio®) is a first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) compound. Xpovio blocks the nuclear export of tumor suppressor, growth regulatory and anti-inflammatory proteins, leading to accumulation of these proteins in the nucleus and enhancing their anti-cancer activity in the cell. The forced nuclear retention of these proteins can counteract a multitude of the oncogenic pathways that, unchecked, allow cancer cells with severe DNA damage to continue to grow and divide in an unrestrained fashion.

SparkCures ID 128
Developed By Karyopharm Therapeutics
Brand Name Xpovio®
Generic Name Selinexor
Additional Names KPT-330
Treatment Classifications
Tags
  • Published Results

Clinical Trials

All Clinical Trials

View all active clinical trials around the US.

Untreated / Newly Diagnosed Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have been newly diagnosed or have not yet received treatment.

Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma
SELINEXOR
View Trial
A Phase II Study of Selinexor In Addition to Lenalidomide for Consolidation and Maintenance Treatment After...
View Trial
Early Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received one to two prior lines of therapy.

Verified
Phase 3 Clinical Trial Comparing the Safety and Effectiveness of Selinexor, Pomalidomide and Dexamethasone vs Elotuzumab, Pomalidomide and Dexamethasone in R...
SELINEXOR
View Trial
Verified
Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma (SELVEDge)
SELVEDGE
View Trial

SparkCures Verified Accurate, up-to-date information. Learn more

A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multipl...
SELINEXOR
View Trial
Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refracto...
View Trial
Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma
View Trial
Selinexor, Carfilzomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
SELINEXOR
View Trial
Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With R...
SCOPE
View Trial
Myeloma-Developing Regimens Using Genomics
MYDRUG
View Trial
Late Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.

Verified
Phase 3 Clinical Trial Comparing the Safety and Effectiveness of Selinexor, Pomalidomide and Dexamethasone vs Elotuzumab, Pomalidomide and Dexamethasone in R...
SELINEXOR
View Trial
Verified
Selinexor Treatment for Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy
View Trial
Verified
Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma (SELVEDge)
SELVEDGE
View Trial

SparkCures Verified Accurate, up-to-date information. Learn more

A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multipl...
SELINEXOR
View Trial
Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refracto...
View Trial
Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma
View Trial
Selinexor, Carfilzomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
SELINEXOR
View Trial
Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With R...
SCOPE
View Trial
Myeloma-Developing Regimens Using Genomics
MYDRUG
View Trial
Smoldering Myeloma

The following is a listing of clinical trials for patients with Smoldering Myeloma.

Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma
View Trial
Monoclonal Gammopathy of Undetermined Significance (MGUS)

Published Results

Phase 3 BOSTON Study Meets Primary Endpoint with Significant Incease in Progression-Free Survival

March 10, 2020

  • Combination of Once-Weekly XPOVIO® (selinexor), Once-Weekly Velcade® (bortezomib) plus Dexamethasone (SVd) Results in Statistically Significant Reduction in the Risk of Disease Progression or Death Compared to Standard Twice-Weekly Velcade® plus Dexamethasone (Vd) Regimen
  • The BOSTON study met its primary endpoint of a statistically significant increase in progression-free survival (PFS).
  • The median PFS in the SVd arm was 13.93 months compared to 9.46 months in the Vd arm, representing a 4.47 month (47%) increase in median PFS (hazard ratio=0.70; p=0.0066). There were no new safety signals on the SVd arm and there was no imbalance in deaths between the two arms in the study.
Read More

Resources

Karyopharm Announces FDA Approval of XPOVIO™ (selinexor) for the Treatment of Patients with Relap...

July 03, 2019

Read More
ASCO 2019: Updates on Selinexor with Paul Richardson, MD, Dana Farber Cancer Institute

June 17, 2019

Read More
FDA advisory committee delays vote on Karyopharm's selinexor

February 26, 2019

Read More
Karyopharm Reports Updated Selinexor Data from the Phase 2b STORM and Phase 1b/2 STOMP Studies in...

September 28, 2018

Read More
Selinexor Gets FDA Fast-Track Status for Penta-Refractory Myeloma Patients

April 12, 2018

Read More
ASH 2017: Expert’s Picks – Selinexor

December 22, 2017

Read More
When It’s Too Late to Join a Clinical Trial and the New Drug Selinexor with Dr. Nikoletta Lendvai...

November 07, 2016

Read More
SparkCures Verified

SparkCures is working closely with Karyopharm Therapeutics to provide the most up-to-date information on this treatment. Use the button above to add this treatment to your list of favorites.

Learn more about how we work with industry partners